Abstract
BackgroundProstate cancer is the most common cancer among men, and its diagnosis and treatment are improving. Our study evaluated how PSMA-PET/CT prior to treatment planning might improve the optimal management of prostate cancer radiotherapy.MethodsThis retrospective pilot study included 43 prostate cancer (PCa) patients referred to our radiation oncologist department, from the urology department, for radiation therapy. 18F-PSMA-PET/CT was ordered by the radiation oncologists mainly due to the lack of resent image staging. The patients were divided into three different groups according to their initially planned treatments: radical radiation therapy (RT) (newly diagnosed PCa patients), salvage RT (patients with biochemical recurrence after radical prostatectomy), or oligometastatic RT (oligometastatic PCa patients with good response after systemic treatment).ResultsFollowing PSMA-PET/CT, the initially planned RT was changed for 60.5% of the patients due to new findings (metastases and/or recurrent disease). The final treatment choice was effected by PSMA-PET/CT outcome in 60.5% (26/43) of the patients, and in 50% (16/32) of patients, the radiation treatment plan changed following PSMA-PET/CT. Only 39.5% (17/43) of the patients who underwent PSMA-PET/CT were treated according to their initial treatment plans.ConclusionsOur results indicate that PSMA-PET/CT impacts treatment decisions and the selection of RT as well as adjuvant treatment protocols in the management of prostate cancer.
Highlights
Prostate cancer (PCa) is the most common cancer among men, but it can often be treated successfully [1]
361 patients had a first visit for radiation treatment planning. 43 of them (12%) had PSMA-PET/computed tomography (CT), which was ordered by our radiation therapy (RT) oncologists if they assessed insufficient imaging information or suspected disease progression
Altogether, 43 PCa patients with PSMA-PET/CT imaging to confirm disease stage were included to the study
Summary
Prostate cancer (PCa) is the most common cancer among men, but it can often be treated successfully [1]. For PCa, new cancer drugs have been adopted in clinical practice, and patient treatment outcomes have improved. PSMA-PET/CT has a higher specificity and sensitivity for the detection of tumor lesions than stand-alone CT, MRI and choline-PET. It offers promising opportunities for treatment individualization and can aid clinicians in making the right treatment decisions [4, 5]. Prostate cancer is the most common cancer among men, and its diagnosis and treatment are improving. Our study evaluated how PSMA-PET/CT prior to treatment planning might improve the optimal management of prostate cancer radiotherapy
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
